BioCryst Pharmaceuticals
BCRX
#4497
Rank
A$3.31 B
Marketcap
A$13.23
Share price
-1.57%
Change (1 day)
18.72%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of December 2025 : A$0.61 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is A$0.61 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2025-12-31A$0.65 B-49.61%
2024-12-31A$1.30 B7.36%
2023-12-31A$1.21 B11.16%
2022-12-31A$1.08 B33.15%
2021-12-31A$0.81 B125.11%
2020-12-31A$0.36 B200.64%
2019-12-31A$0.12 B37.78%
2018-12-31A$87.75 M25.2%
2017-12-31A$70.09 M-5.95%
2016-12-31A$74.53 M79.91%
2015-12-31A$41.42 M13.01%
2014-12-31A$36.65 M8.99%
2013-12-31A$33.63 M16.5%
2012-12-31A$28.86 M-1.33%
2011-12-31A$29.25 M
2000-12-31A$0.01 M
1997-12-31A$0.15 M-59.36%
1996-12-31A$0.37 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Gilead Sciences
GILD
A$35.04 B 5,581.81%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$33.53 B 5,337.53%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
A$1.46 B 136.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.96 B 57.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
A$0.34 B-43.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
A$3.28 M-99.47%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
A$2.1 M-99.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
A$13.18 M-97.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
A$0.93 B 51.09%๐Ÿ‡บ๐Ÿ‡ธ USA